Loading…

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

[...]GLP-1 RAs and SGLT-2 inhibitors are usually introduced at a similar T2D disease stage. [...]the fixed-effect estimates are relative levels of the outcome variable and estimated SD of random effects are interpretable as coefficients of variation.8 For the (log) distance between phlebotomies, a s...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open diabetes research & care 2023-06, Vol.11 (3), p.e003300
Main Authors: Bain, Stephen C, Carstensen, Bendix, Hyveled, Liselotte, Seremetis, Stephanie, Flindt Kreiner, Frederik, Amadid, Hanan, Clark, Alice
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]GLP-1 RAs and SGLT-2 inhibitors are usually introduced at a similar T2D disease stage. [...]the fixed-effect estimates are relative levels of the outcome variable and estimated SD of random effects are interpretable as coefficients of variation.8 For the (log) distance between phlebotomies, a simple random person effect was used, and only a single exposure variable for GLP-1 was used as fixed effect. In the ferritin dataset, 85% had a duration of HH of 0–15 years, whereas duration of drug exposure was mostly less than 5 years. [...]we showed relative ferritin levels across a HH duration of 0–15 years, using ferritin levels at 5 years of HH duration for a person not exposed to either drug class as reference. All data processing and analysis was done on anonymized data at Statistics Denmark’s server; SAS V.9.4 was used for data handling and R 4.1.0 with the Epi package was used for statistical analyses.
ISSN:2052-4897
2052-4897
DOI:10.1136/bmjdrc-2022-003300